An Extension of Istradefylline in North American Parkinson's Disease Patients Who Have Completed Study 6002-INT-001
NCT ID: NCT00199381
Last Updated: 2024-05-17
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE3
504 participants
INTERVENTIONAL
2005-10-31
2008-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
An Extension of Istradefylline in Parkinson's Disease Patients Who Have Completed Studies 6002-EU-007, 6002-US-013 or 6002-US-018
NCT00199368
Long-Term Safety Study of KW-6002 (Istradefylline) in Parkinson's Disease Patients
NCT00957203
A Study of Istradefylline (KW-6002) for the Treatment of Parkinson's Disease
NCT00250393
A Study of Istradefylline (KW-6002) as Monotherapy in Parkinson's Disease (PD) Patients
NCT00199433
Study of KW-6002 (Istradefylline) in Parkinson's Disease in Patients With Motor Response Complications on Levodopa
NCT00203957
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Single Arm
Treatment with oral istradefylline (KW-6002) 20 or 40 mg once daily.
Istradefylline
Oral istradefylline (KW-6002) 20 or 40 mg once daily.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Istradefylline
Oral istradefylline (KW-6002) 20 or 40 mg once daily.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Not of childbearing potential
Exclusion Criteria
* ALT/AST levels \> 2.5 times ULN
30 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Kyowa Kirin Co., Ltd.
INDUSTRY
Kyowa Kirin, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Neil Sussman, MD
Role: STUDY_DIRECTOR
Kyowa Kirin, Inc.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Kyowa Pharmaceutical Inc.
Princeton, New Jersey, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
6002-US-025
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.